Clinical Trials Arena on MSN17d
Biohaven’s pivotal bipolar drug trial fails, stock takes hit
Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial, sinking the company’s stock price. The US-based biotech shared the announcement as ...
Investor's Business Daily on MSN17d
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity
The drug works by activating Kv7, a channel that regulates electrical impulses and neurotransmitter release between neurons. The approach hasn't been validated in bipolar mania. The "lowest risk ...
Autoblog14y
Kia bringing KV7 gullwing concept to Detroit
they're not just for SLS AMG owners or Back to the Future fans anymore. Kia is bringing its KV7 crossover concept to the 2011 Detroit Auto Show, and the ingress/egress on it looks to be pretty simple.
Pharmabiz8d
QurAlis announces positive data from phase 1 trial of QRL-101 evaluating biomarkers of ALS and epilepsy in healthy volunteers
QRL-101-03 (NCT06532396) is a randomized, double-blind, placebo-controlled, multiple-ascending dose clinical trial evaluating the safety, tolerability, and PK of QRL-101 in up to 60 healthy ...
The Globe and Mail23d
Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update
“We also expect multiple regulatory filings in 2025 coming out of our early-stage portfolio – which includes Kv7 and Nav1.7 candidates that are progressing through IND-enabling studies – to support ...